Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors
| Autor: | Nicola Brownlow, N J Dibb, Alison Russell, Maria Kinigopoulou, Andreas G. Tzakos, Konstantinos Skobridis, Jan Domin, Serafim Kiriakidis, Roberta Sala, Emilia Giannousi, Vassiliki Theodorou, Rakhee Chauhan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Fusion Proteins
bcr-abl Drug design Antineoplastic Agents Receptor Macrophage Colony-Stimulating Factor Biology Pharmacology Biochemistry Piperazines Substrate Specificity Mice Cell Line Tumor hemic and lymphatic diseases Drug Discovery medicine Animals Humans Computer Simulation Receptors Platelet-Derived Growth Factor Phosphorylation General Pharmacology Toxicology and Pharmaceutics Protein Kinase Inhibitors neoplasms Binding Sites ABL Organic Chemistry Imatinib Proto-Oncogene Proteins c-kit Pyrimidines Imatinib mesylate Drug Design Benzamides Imatinib Mesylate biology.protein Molecular Medicine K562 Cells Tyrosine kinase Platelet-derived growth factor receptor K562 cells medicine.drug |
| Zdroj: | ChemMedChem. 5(1) |
| ISSN: | 1860-7187 1860-7179 |
| Popis: | Imatinib is a clinically important ATP analogue inhibitor that targets the tyrosine kinase domain of the intracellular Abl kinase and the PDGF receptor family. Imatinib has revolutionised the treatment of chronic myeloid leukaemia, which is caused by the oncogene Bcr-Abl and certain solid tumours that harbor oncogenic mutations of the PDGF receptor family. As a leading kinase inhibitor, imatinib also provides an excellent model system to investigate how changes in drug design impact biological activity, which is an important consideration for rational drug design. Herein we report a new series of imatinib derivatives that in general have greater activity against the family of PDGF receptors and poorer activity against Abl, as a result of modifications of the phenyl and N-methylpiperazine rings. These new compounds provide a platform for further drug development against the therapeutically important PDGF receptor family and they also provide insight into the engineering of drugs with altered biological activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text